Eline Schreuders

Eline Schreuders

Auto-generated profile, based on publicly available information

Eline Schreuders

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2015 in Gut
Verified
Journal Article
Open access
PDF file
ESEline H Schreuders
Eline H Schreuders
ARArlinda Ruco
Arlinda Ruco
LRLinda Rabeneck
Linda Rabeneck
RSRobert E Schoen
Robert E Schoen
JSJoseph JY Sung
Joseph JY Sung
EKErnst J Kuipers
Ernst J Kuipers
Colorectal cancer (CRC) ranks third among the most commonly diagnosed cancers worldwide, with wide geographical variation in incidence and mortality across the world. Despite proof that screening can decrease CRC incidence and mortality, CRC screening is only offered to a small proportion of the target population worldwide. Throughout the world there are widespread differences in CRC screening implementation status and strategy. Differences can be attributed to geographical variation in CRC incidence, economic resources, healthcare structure and infrastructure to support screening such as the ability to identify the target population at risk and cancer registry availability. This review highlights issues to consider when implementing a CRC screening programme and gives a worldwide overview of CRC burden and the current status of screening programmes, with focus on international differences.

1 November 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
EGEsmée J. Grobbee
Esmée J. Grobbee
ESEline H. Schreuders
Eline H. Schreuders
BHBettina E. Hansen
Bettina E. Hansen
MBMarco J. Bruno
Marco J. Bruno
ILIris Lansdorp-Vogelaar
Iris Lansdorp-Vogelaar
EKErnst J. Kuipers
Ernst J. Kuipers

22 June 2018 in Gut
Verified
Journal Article
Closed access
PDF file
EWEls Wieten
Els Wieten
ESEline H Schreuders
Eline H Schreuders
EGEsmée J Grobbee
Esmée J Grobbee
DNDaan Nieboer
Daan Nieboer
WBWichor M Bramer
Wichor M Bramer
MSManon C W Spaander
Manon C W Spaander
Objective: Faecal immunochemical tests (FITs) are replacing guaiac faecal occult blood tests (gFOBTs) for colorectal cancer (CRC) screening. Incidence of interval colorectal cancer (iCRC) following a negative stool test result is not yet known. We aimed to compare incidence of iCRC following a negative FIT or gFOBT. Design: We searched Ovid Medline, Embase, Cochrane Library, Science Citation Index, PubMed and Google Scholar from inception to 12 December 2017 for citations related to CRC screening based on stool tests. We included studies on FIT or gFOBT iCRC in average-risk screening populations. Main outcome was pooled incidence rate of iCRCs per 100 000 person-years (p-y). Pooled incidence rates were obtained by fitting random-effect Poisson regression models. Results: We identified 7 426 records and included 29 studies. Meta-analyses comprised data of 6 987 825 subjects with a negative test result, in whom 11 932 screen-detected CRCs and 5 548 gFOBT or FIT iCRCs were documented. Median faecal haemoglobin (Hb) positivity cut-off used was 20 (range 10–200) µg Hb/g faeces in the 17 studies that provided FIT results. Pooled incidence rates of iCRC following FIT and gFOBT were 20 (95% CI 14 to 29; I 2 =99%) and 34 (95% CI 20 to 57; I 2 =99%) per 100 000 p-y, respectively. Pooled incidence rate ratio of FIT versus gFOBT iCRC was 0.58 (95% CI 0.32 to 1.07; I 2 =99%) and 0.36 (95% CI 0.17 to 0.75; I 2 =10%) in sensitivity analysis. For every FIT iCRC, 2.6 screen-detected CRCs were found (ratio 1:2.6); for gFOBT, the ratio between iCRC and screen-detected CRC was 1:1.2. Age below 60 years and the third screening round were significantly associated with a lower iCRC rate. Conclusion: A negative gFOBT result is associated with a higher iCRC incidence than a negative FIT. This supports the use of FIT over gFOBT as CRC screening tool.

29 January 2016 in Current Treatment Options in Gastroenterology
Verified
Journal Article
Open access
PDF file
ESEline H. Schreuders
Eline H. Schreuders
EGEsmée J. Grobbee
Esmée J. Grobbee
MSManon C. W. Spaander
Manon C. W. Spaander
EKErnst J. Kuipers
Ernst J. Kuipers
Opinion statement Colorectal cancer (CRC) forms an important public health problem, especially in developed countries. CRC screening tests can be used to identify asymptomatic individuals with CRC precursors and (early) cancer. Removal of these lesions reduces CRC incidence and prevents CRC-related mortality. There are a range of screening tests available, each with advantages and disadvantages. Stool screening tests can broadly be divided into fecal occult blood tests (FOBTs) and molecular biomarker test, such as DNA/RNA marker tests, protein markers, and fecal microbiome marker tests. Guaiac fecal occult blood tests (gFOBT) have been demonstrated in large randomized screening trials to reduce CRC mortality. Fecal immunochemical tests (FIT) have superior adherence, usability, and accuracy as compared to gFOBT. Advantage of the use of quantitative FITs in CRC screening programs is the cut-off level that can be adjusted. Molecular biomarker DNA tests have shown to detect significantly more cancers than FIT. By combining biomarker DNA tests with FIT, sensitivity for advanced adenomas can be increased significantly. However, it has lower specificity thus demands more colonoscopy resources, is more cumbersome, and costly. The adherence has not been assessed in population screening trials. For these reasons, FIT is therefore at present regarded as the preferred method of non-invasive CRC screening. This chapter will review the current status of fecal test-based CRC screening.

1 January 2011 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
DKDina Kao
Dina Kao
ELEoin Lalor
Eoin Lalor
GSGurpal Sandha
Gurpal Sandha
RFRichard N Fedorak
Richard N Fedorak
BKBloeme van der Knoop
Bloeme van der Knoop
SZSander Veldhuyzen van Zanten
Sander Veldhuyzen van Zanten
BACKGROUND: The ideal bowel cleansing regimen for colonoscopy has yet to be determined.OBJECTIVE: To compare the cleansing efficacy, and patient tolerability and safety of four bowel preparation regimens.METHODS: A total of 834 patients undergoing outpatient colonoscopy were randomly assigned to one of four regimens: 4 L polyethylene glycol (PEG); 2 L PEG + 20 mg bisacodyl; 90 mL of sodium phosphate (NaP); or two sachets of a commercially available bowel cleansing solution (PSMC) + 300 mL of magnesium citrate (M). The primary outcome measure was cleansing efficacy, which was scored by blinded endoscopists using the Ottawa Bowel Preparation Scale. Secondary outcome measures were bowel preparation quality according to time of colonoscopy, and patient tolerability and safety.RESULTS: The mean total cleansing score was significantly worse in the NaP group compared with the other three groups (P<0.0001). The mean cleansing scores were worse in patients who underwent morning versus afternoon colonoscopy, a finding that was consistent in all four groups. PSMC + M was the best tolerated regimen. No clinically significant mean changes in creatinine or electrolyte levels were identified, although a significantly higher proportion of patients in the NaP group developed hypokelemia (P<0.0001).CONCLUSIONS: 2 L PEG + 20 mg bisacodyl, or PSMC + M was as efficacious as 4 L PEG and superior to NaP for bowel cleansing. A short interval between the completion of bowel preparation and the start of colonoscopy (ie, ‘runway time’), irrespective of bowel preparation regimen, appeared to be a more important predictor of bowel cleanliness than the cathartic agents used.

1 August 2019 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
ESEline H Schreuders
Eline H Schreuders
EGEsmée J Grobbee
Esmée J Grobbee
SNStella A V Nieuwenburg
Stella A V Nieuwenburg
AKAtija Kapidzic
Atija Kapidzic
ARAafke H C van Roon
Aafke H C van Roon
MSManon C.W. Spaander
Manon C.W. Spaander